MDC 2021 - Our Life Saving Orphan Drug Candidate for UK Clinical Trials

Innovation in Skin Oncology

MedC Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing and commercializing a novel class of therapeutics.

CTCL (Cutanous T-Cell Lymphoma) is a non-melanoma cancer which express itself primarily on the skin.

Sezary Syndrome is a highly lethal Orphan Disease for unmet needs.

MF is more common and less lethal.

At MedC we have developed therapeutics for both Sezary and MF and plan to enter into clinical studies during 2023.

This very common pre-skin cancer condition usually requires invasive removal, often is multiple locations.

Our innovative topical treatment will cancel the need for "going under the knife" repeatedly.